CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
CRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.
How this was made
The 30-second read
Why it matters
The earnings beat and improved loss profile, combined with strong Casgevy sales growth and a sizable cash runway, can support valuation and near-term positioning. The main forward driver highlighted is the expected stream of clinical updates in the second half of 2026.
Market read
Traders get a concrete earnings datapoint (loss and revenue vs consensus) plus partner-driven product sales momentum and cash runway, which can influence short-term biotech sentiment and positioning ahead of 2H clinical catalysts.
What to watch
The article flags multiple pipeline updates expected in 2H 2026, but provides no new efficacy/safety data here; traders may re-rate only after those clinical catalysts arrive.
Background
Zacks reports CRISPR Therapeutics’ Q2 2026 financial results, Casgevy commercial momentum via Vertex, cost controls, cash position, and pipeline status across multiple programs.
Ticker impact
CRISPR Therapeutics reported Q2 2026 results with a narrower loss and revenues of $10.2M, beating consensus, plus detailed cost and cash updates.
Likely modest positive bias for the next few sessions as traders digest the earnings beat and cash runway, with follow-through tied to upcoming 2H clinical updates.
The article provides concrete Q2 financial datapoints (loss and revenue vs consensus), plus specific Casgevy sales momentum and cash at quarter-end. However, it is still a Zacks-style earnings recap without explicit new guidance or a fresh regulatory/clinical readout in this text.
Market effects
Reinforces commercial traction for gene-editing therapies and may improve sentiment toward partnered platforms with similar commercialization models.
Casgevy expansion details across the US, Europe, Germany reimbursement, and UK/Saudi filings highlight broader international adoption signals.
International regulatory progress and reimbursement milestones suggest scaling beyond initial launch geographies, supporting global biotech risk appetite.
Counterpoint
Despite the beat, the company’s core economics remain heavily dependent on Casgevy partner performance and collaboration expense dynamics, which can swing quarter to quarter.
Key entities
- companyCRISPR Therapeutics
Subject of the article, reporting Q2 2026 results and providing pipeline and cash updates.
- companyVertex Pharmaceuticals
Partner on Casgevy; reported $76M Q2 sales and related commercialization milestones that flow into CRSP collaboration economics.
- productCasgevy
CRISPR/Cas9 gene therapy whose regulatory expansion and sales momentum are cited as a key commercial driver.
